← 返回

在小鼠中构建 NK 细胞淋巴瘤模型揭示其起源细胞和微环境变化并确定治疗靶点

英文原题:Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets.

查看英文原题

Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets.

PubMed 2024/10/22(内容时间) Nat Commun Q1 · IF 18.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

结外NK/T细胞淋巴瘤(ENKTCL)是一种与Epstein-Barr病毒(EBV)相关的肿瘤,优先累及上呼吸消化道。在此,我们展示小鼠中NK细胞特异性的Trp53破坏会导致经过较长潜伏期后发生NK细胞淋巴瘤,不仅累及造血系统,还累及唾液腺。在肿瘤发生前,Trp53敲除引起广泛的基因表达变化,导致未成熟NK细胞扩增,且仅局限于唾液腺。人类和小鼠NK细胞淋巴瘤均表达组织驻留标志物,提示组织驻留NK细胞是其起源细胞。小鼠NK细胞淋巴瘤显示反复出现的Myc扩增和MYC靶基因特征的上调。EBV编码的潜伏膜蛋白1表达加速NK细胞淋巴瘤发生,并通过干扰素-γ信号引起多种微环境变化,尤其是髓系细胞扩增。反过来,髓系细胞通过CXCL16-CXCR6信号支持肿瘤细胞,其抑制在体内对NK细胞肿瘤有效。

值得注意的是,表达KLRG1的细胞在肿瘤中扩增,并能够在二次受体中重建肿瘤。此外,单独靶向KLRG1或与使用eIF4抑制剂的MYC抑制联合,对NK细胞肿瘤有效。

因此,我们的观察为发病机制提供了见解,并强调了ENKTCL中的潜在治疗靶点,包括CXCL16、KLRG1和MYC,这有助于改进其诊断和治疗策略。

展开英文摘要原文

Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm preferentially involving the upper aerodigestive tract.

Here we show that NK-cell-specific Trp53 disruption in mice leads to the development of NK-cell lymphomas after long latency, which involve not only the hematopoietic system but also the salivary glands. Before tumor onset, Trp53 knockout causes extensive gene expression changes, resulting in immature NK-cell expansion, exclusively in the salivary glands. Both human and murine NK-cell lymphomas express tissue-resident markers, suggesting tissue-resident NK cells as their cell-of-origin.

Murine NK-cell lymphomas show recurrent Myc amplifications and upregulation of MYC target gene signatures. EBV-encoded latent membrane protein 1 expression accelerates NK-cell lymphomagenesis and causes diverse microenvironmental changes, particularly myeloid propagation, through interferon-γ signaling. In turn, myeloid cells support tumor cells via CXCL16-CXCR6 signaling and its inhibition is effective against NK-cell tumors in vivo. Remarkably, KLRG1-expressing cells expand in the tumor and are capable of repopulating tumors in secondary recipients.

Furthermore, targeting KLRG1 alone or combined with MYC inhibition using an eIF4 inhibitor is effective against NK-cell tumors.

Therefore, our observations provide insights into the pathogenesis and highlight potential therapeutic targets, including CXCL16, KLRG1, and MYC, in ENKTCL, which can help improve its diagnostic and therapeutic strategies.

论文信息

作者
Koya J、Tanigawa T、Mizuno K、Kim H、Ito Y、Yuasa M、Yamaguchi K、Kogure Y
第一作者单位
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.Japan
通讯作者单位
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. kkataoka-tky@umin.ac.jp.Japan
文献类型
非美国政府资助研究
期刊
Nature communications2024 Oct 22
原文标识
PubMed 39438472 · DOI 10.1038/s41467-024-53376-1